Study of Pembrolizumab, Binimetinib, and Bevacizumab in Patients With Refractory Colorectal Cancer

NCT03475004 · clinicaltrials.gov ↗

PHASE2

Phase

COMPLETED

Status

53

Enrollment

OTHER

Sponsor class

Conditions

Colorectal Cancer
Metastatic Cancer

Interventions

DRUG: Pembrolizumab
DRUG: Bevacizumab
DRUG: Binimetinib

Sponsor

University of Colorado, Denver